Webinar: Proposed Changes to the Medicare Physician Fee Schedule and Quality Payment Program Just Released: What You Need to Know and Action Steps to Take Now to Protect Your Lab’s Revenue

Proposed Changes to Medicare Physician Fee Event

At end of day Thursday, July 12, the CMS released its proposed Medicare Physician Fee Schedule for 2019. The projected rules update rates and policies applicable to Medicare physicians and other professionals under Medicare, and also include updates to Medicare rates and policies under Part B, as well as to the Quality Payment Program which implements the Merit-Based Incentive Payment System (MIPS) and Alternative Payment Models (APMs). This is the first year CMS included updates to the Quality Payment Program (QPP) in the proposed fee schedule.

In this webinar, attendees will learn:

  • What do the various changes mean?
  • What is their impact to labs and pathology practices?

Featured XIFIN Speaker

Lâle White, Executive Chairman & CEO, XIFIN, Inc.

Lâle White is a nationally recognized expert in the field of medical financial management and regulatory compliance, with over 35 years of experience in information systems development and medical billing. She lectures extensively on these topics and has consulted for major laboratories and laboratory associations throughout the US. She worked with HCFA and the US Office of the Inspector General to develop the first OIG Model Compliance Program. Lâle was previously Vice President - Finance of Laboratory Corporation of America (NYSE: LH), one of the largest clinical reference laboratories in the US, and its predecessor National Health Laboratories (NYSE: NHLI), where she led the software development of several accounts receivable, inventory, cost accounting and financial management systems for the laboratory industry. Lâle has a BA in finance and an MBA from Florida International University. She previously served on the Board of Directors for bioTheranostics, part of the worldwide bioMerieux group, and is currently a member of the Board of Directors for CombiMatrix Corporation, a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders.

Featured XIFIN Speaker

Kyle Fetter, Executive Vice President & General Manager of Diagnostic Services, XIFIN, Inc.

Kyle Fetter has implemented and overseen the commercialization, billing, and reimbursement processes for over 70 unique molecular diagnostic companies releasing new high complexity laboratory testing services onto the health care market. He currently provides strategic direction as well as oversees the implementation process for molecular diagnostic companies at various stages of commercialization and third party payer contracting. He also oversees the development and commercialization of new web-based software products at XIFIN catered to high complexity testing laboratories. In addition to actively working with XIFIN’s large molecular diagnostic billing department, he consults with molecular diagnostic companies on projecting cash flow for non-covered services, implementing successful appeals strategies, and how to effectively manage the relationship between sales and reimbursement for new medical technology. Kyle regularly provides insights into the changing landscape of molecular diagnostic reimbursement via webinars, conferences, and XIFIN’s blog. He came to the healthcare industry with a background in technology funding and commercialization. Kyle has a B.A. from the University of Southern California and an M.B.A from the University of Utah.

Featured XIFIN Speaker

Diana Brooks, Director of Anatomic Pathology Program Development, XIFIN, Inc.

Diana Brooks is the Director of the Anatomic Pathology Program Development at XIFIN, providing strategic support for pathology operations and clients. With more than 14 consecutive years of working in the Pathology and Laboratory industry, Diana has an exceptional understanding of market landscape. She has worked with pathology practices nationwide, helping them to improve their revenue cycle performance, offering direction for growth and development, exploring financially related process improvement opportunities, and developing strategic partnerships with a variety of pathology practices, of all scopes and sizes, around the country. Diana’s previous roles include senior level business development, client management, billing performance analysist, internal auditor, and marketing coordination. Diana holds a B.A. in Marketing as well as Economics from Francis Marion University.

Additional Speaker

Mick Raich, President and Chief Executive Officer,Vachette Pathology

Mick Raich is the founder of Vachette Pathology. He is a nationally recognized consultant in the business of pathology and laboratory billing. His easy style and get-it-done personality have allowed him to become the industry leader in this field. Mr. Raich has spent his entire 26 year career in healthcare. His experience includes direct patient care, hospital management, and working at a pathology billing company. Since 2001, Mr. Raich has served as the President/CEO of Vachette Pathology.Over the years Mr. Raich has presented at every major national pathology and laboratory society conference and numerous state societies. He is frequently quoted, interviewed, and published as a specialist in this field. Mr. Raich is an ardent supporter of PathPAC and a member of MGMA.


Richard Faherty, Managing Director, The Dark Intelligence Group, Inc.

Richard Faherty is currently consulting primarily with laboratory services.  He was the Executive Vice President, Administration, for BioReference Laboratories (BRLI) until his retirement in July 2017.  He spent more than 20 years at BRLI overseeing general corporate affairs as well as all technology; he was President of PSIMedica (the Company’s clinical knowledge management division) and the creator of CareEvolve, the Company’s connectivity solution up until its recent sale to ELLKAY.  Prior to BRLI, Faherty worked in financial technology at S&P Comstock and A-T Financial Services, as well as a Y2K project manager for MetLife. He has been associated with the clinical laboratory business since 1986 when he began consulting for GenCare Biomedical (later acquired by BioReference). Faherty is a graduate of the University of Notre Dame and Fordham Law School. After practicing law for nearly ten years, he became involved in Information Technology and has been involved with complex data management, networking solutions, and application and data distribution since that time.


Pathology Webinars
Proposed Changes to the Medicare Physician Fee Schedule and Quality Payment Program Just Released: What You Need to Know and Action Steps to Take Now to Protect Your Lab’s Revenue